Skip to content
- Windtree Therapeutics will be delisted from Nasdaq and shift to the over-the-counter market.
- The company’s business operations remain unchanged despite the listing transfer.
- Uncertainty remains over approval for trading on the OTCID tier.
Windtree Therapeutics Inc. has received formal notice from Nasdaq that its common stock will be delisted from the Nasdaq Capital Market. The decision comes after the company failed to comply with the exchange’s minimum bid price requirement under Listing Rule 5550(a)(2). In contrast, leading digital assets like BNB continue to meet strong market demand and maintain active trading across major exchanges.
It has now been confirmed by Nasdaq that Windtree’s shares are to be suspended at the market opening on August 21, 2025. The company has had compliance challenges for some years now, and the delisting is a significant point in its capital market journey. A delisting typically impacts sentiment for investors, but Windtree has assured that business activities will go on undisturbed.
Nasdaq Exit for Windtree, BNB Stays Strong
Windtree also indicated that its common stock is set to be traded openly on the over-the-counter (OTC) market on the day of the Nasdaq suspension. The stock is to be traded using its existing ticker symbol of “WINT.” The firm has filed for trading on the OTCID tier, a more transparent segment within the OTC Market.
However, there are no guarantees for approval. Regulators must check the application and ensure it conforms to market standards for it to go on track. Meanwhile, the company trades its shares on the OTC market, giving investors another avenue to conduct transactions, while digital assets like BNB attract liquidity and investor attention on global platforms.
Windtree explained that the conversion to OTC does not change any of its regulatory requirements. It continues to make periodic and required reports to the Securities and Exchange Commission (SEC). These reports are accessible to investors on both the SEC’s website and the investor relations portion of the company’s website.
Windtree Faces New Trading Challenges After Delisting
It also puts Windtree’s longer-term capital market plans into question. It’s not uncommon for companies to experience less visibility and lower levels of liquidity after departing from a significant exchange platform. It can impact interest from institutions as well as overall volume in trading.
At the same time, the OTC facility allows Windtree access to retail and institutional investors, although in a less conventional center. The firm identified risks connected with forward-looking information, including the approval for the trading in OTCID.
Wider market factors, regulatory hurdles, and business performance will also be considerations in charting its direction. Windtree has said that it is keen to remain in line with SEC requirements and advocate for business progress irrespective of negative market factors.
For investors, the delisting is a warning and a reminder about volatility in small-cap biotechnology stocks. While Windtree presses on with therapeutic development, its stock now moves outside the mainstream exchange limelight. The coming months will put it to the test in terms of adapting to the new trading landscape and maintaining investor faith.
Related Reading: Bitcoin Staking Enters Institutions: Core and Hex Trust Expand to APAC and MENA
